RxDoctor Payments Data

Linda Winful

Psychiatric/Mental Health · Montclair, NJNPI 1649703299

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,750 of the $39,966 with a category attached, or 86.9%. AbbVie accounts for 96.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $12,701 and has fallen 51.2% since, to $6,196 in 2025. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,966in general payments, 2019–2025

Across 214 payments — averaging $186.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$39K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$363
  • Neurocrine Biosciences, Inc.$323
  • Johnson & Johnson$321
  • Vanda Pharmaceuticals Inc.$135
  • Axsome Therapeutics, Inc.$117
  • plus $155 from 4 others

What the payments were for

  • Speaking & faculty fees$34,75087%
  • Travel & lodging$1,4204%
  • Food & beverage$3,6469%
  • Education$1500%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,966 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$61,446
Medicare patients
24
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl19$27,228
Aripiprazole18$1,452
Quetiapine Fumarate27$900
Olanzapine19$694
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$685
Escitalopram Oxalate91$643
Bupropion XlBupropion Hcl25$403
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$339
Lamotrigine26$282
Hydroxyzine Hcl12$251
Alprazolam37$213
Trazodone Hcl26$212
Duloxetine Hcl35$164
Venlafaxine Hcl ErVenlafaxine Hcl20$157
Risperidone18$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$38,551$27,22819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Montclair

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →